Artunc Ferruh, Nowak Albina, Mueller Christian, Breidthardt Tobias, Twerenbold Raphael, Wagner Robert, Peter Andreas, Haering Hans-Ulrich, Ebmeyer Stefan, Friedrich Bjoern
Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, University of Tuebingen, Tuebingen, Germany.
Division of Internal Medicine, Division of Nephrology, University of Zurich, Zurich, Switzerland.
PLoS One. 2014 Jan 22;9(1):e86148. doi: 10.1371/journal.pone.0086148. eCollection 2014.
Vasopressin, endothelin and adrenomedullin are vasoactive peptides that regulate vascular tone and might play a role in hypertensive diseases. Recently, laboratory assays have been developed to measure stable fragments of vasopressin, endothelin and adrenomedullin. Little is known about their diagnostic and prognostic value in hemodialysis patients. In this study, we measured the plasma concentration of copeptin, mid-regional-pro-adrenomedullin (MR-pro-ADM) and C-terminal pro-endothelin 1 (CT-pro-ET1) in stable ambulatory hemodialysis patients (n = 239) and investigated their associations with clinical factors and mortality. In all patients enrolled, the plasma concentrations of copeptin, MR-pro-ADM and CT-pro-ET1 were largely elevated with a median concentration of 132 pmol/L (interquartile range [IQR] 78-192) for copeptin, 1.26 nmol/L (IQR 1.02-1.80) for MR-pro-ADM and 149 pmol/L (IQR 121-181) for CT-pro-ET1. The plasma concentrations of all vasoactive peptide fragments correlated with time on dialysis and plasma β2-microglobulin concentration and were negatively correlated to residual diuresis. The plasma concentration of MR-pro-ADM was a strong predictor of all-cause (univariate hazard ratio for a 10-fold increase 9.94 [3.14;32], p<0.0001) and cardiovascular mortality (hazard ratio 34.87 [5.58;217], p = 0.0001) within a 3.8-year follow-up. The associations remained stable in models adjusted for dialysis specific factors and were attenuated in a full model adjusted for all prognostic factors. Plasma copeptin concentration was weakly associated with cardiovascular mortality (only in univariate analysis) and CT-pro-ET1 was not associated with mortality at all. In conclusion, vasoactive peptide fragments are elevated in hemodialysis patients because of accumulation and, most likely, increased release. Increased concentrations of MR-pro-ADM are predictive of mortality.
血管加压素、内皮素和肾上腺髓质素是调节血管张力的血管活性肽,可能在高血压疾病中发挥作用。最近,已经开发出实验室检测方法来测量血管加压素、内皮素和肾上腺髓质素的稳定片段。关于它们在血液透析患者中的诊断和预后价值知之甚少。在本研究中,我们测量了稳定的门诊血液透析患者(n = 239)中copeptin、中段前肾上腺髓质素(MR-pro-ADM)和C末端前内皮素1(CT-pro-ET1)的血浆浓度,并研究了它们与临床因素和死亡率的关联。在所有纳入的患者中,copeptin、MR-pro-ADM和CT-pro-ET1的血浆浓度大幅升高,copeptin的中位数浓度为132 pmol/L(四分位间距[IQR] 78 - 192),MR-pro-ADM为1.26 nmol/L(IQR 1.02 - 1.80),CT-pro-ET1为149 pmol/L(IQR 121 - 181)。所有血管活性肽片段的血浆浓度与透析时间和血浆β2-微球蛋白浓度相关,并与残余尿量呈负相关。在3.8年的随访中,MR-pro-ADM的血浆浓度是全因死亡率(单因素风险比,每增加10倍为9.94 [3.14;32],p<0.0001)和心血管死亡率(风险比34.87 [5.58;217],p = 0.0001)的有力预测指标。在针对透析特定因素调整的模型中,这些关联保持稳定,而在针对所有预后因素调整的完整模型中则有所减弱。血浆copeptin浓度与心血管死亡率弱相关(仅在单因素分析中),而CT-pro-ET1与死亡率完全无关。总之,由于蓄积以及很可能是释放增加,血液透析患者的血管活性肽片段升高。MR-pro-ADM浓度升高可预测死亡率。